Colossal Biosciences operates at the frontier of 'biology as code,' a domain where AI agents are becoming indispensable for sequence design and laboratory automation. Their work requires massive scale genomic alignment and protein modeling to ensure that edits to a modern genome will result in the desired phenotypic traits of an extinct species.
While Colossal is not a core AI agent company, they are a primary consumer of the computational infrastructure that agents help manage. Their spin-off, Form Bio, specifically addresses the need for AI-driven workflows in synthetic biology. For those in the agent ecosystem, Colossal represents a high-stakes deployment environment where agents could eventually automate the design-build-test-learn cycle of genetic engineering, moving from digital sequence design to physical lab execution.
Colossal Biosciences is an attempt to turn conservation into a hard engineering discipline. Founded in 2021 by serial entrepreneur Ben Lamm and Harvard geneticist George Church, the company operates on the premise that extinction is a solvable technical hurdle rather than a permanent biological state. While the public focus often lands on the woolly mammoth or the dodo, the underlying business is a bet on the convergence of CRISPR, synthetic biology, and high-performance computing.
The technical challenge of de-extinction involves more than just finding DNA. It requires editing the genome of a living relative to express the traits of an extinct ancestor. For the woolly mammoth, this means identifying the specific genes responsible for cold tolerance—hair growth, subcutaneous fat, and hemoglobin adaptations—and splicing them into the genome of an Asian elephant. This is not a cloning project. It is a massive genetic modification project aimed at creating a functional proxy that can fulfill the ecological role of the original species.
Colossal builds its own tools because the existing biotechnology stack is often insufficient for the scale they require. This has led to the development of artificial womb technology for exogenous fetal development, which is necessary because the gestation periods and physical requirements for a mammoth-sized calf are too taxing for a surrogate elephant population. The company also developed significant internal software for managing genomic data, a project that became so substantial it was spun off into an independent company, Form Bio.
The company is headquartered in Dallas, Texas, though its scientific operations are distributed across various laboratories and partnerships. These include work with the University of Melbourne for the thylacine (Tasmanian tiger) and IPB University for rhinoceros conservation. This distributed model allows them to tap into specialized expertise in marsupial biology, avian genomics, and mammalian embryology simultaneously.
Critics often point to the high cost of de-extinction compared to traditional conservation. Colossal’s counter-argument is that the technologies they develop for these projects have immediate applications in human health and biodiversity. For instance, their research into elephant endotheliotropic herpesvirus (EEHV) aims to save living elephant populations while they work on the mammoth.
The company has raised over $225 million from a diverse group of investors, including Thomas Tull’s Tulco, At One Ventures, and In-Q-Tel. This funding reflects a belief that Colossal’s breakthroughs in multiplexed gene editing and reproductive technologies will yield patents and processes valuable far beyond the niche of de-extinction. By positioning themselves at the intersection of genetic engineering and climate tech, Colossal is attempting to prove that restoring lost species is a mechanism for stabilizing fragile ecosystems like the Arctic tundra.
A suite of genetic engineering and embryology tools designed to restore extinct species.
Colossal Biosciences is hiring